
Guidance for Industry Population Pharmacokinetics

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)

February 1999
CP 1

Guidance for Industry

Population Pharmacokinetics

Additional copies are available from:

*Office of Training and Communications
Division of Communications Management
Drug Information Branch, HFD-210
5600 Fishers Lane
Rockville, MD 20857
(Tel) 301-827-4573*

<http://www.fda.gov/cder/guidance/index.htm>

or

*Office of Communication,
Training, and Manufacturers Assistance (HFM-40)
Center for Biologics Evaluation and Research (CBER)
1401 Rockville Pike, Rockville, MD 20852-1448
<http://www.fda.gov/cber/guidelines.htm>
(Fax) 888-CBERFAX or 301-827-3844
(Voice Information) 800-835-4709 or 301-827-1800*

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
February 1999
CP 1

TABLE OF CONTENTS

TABLE OF CONTENTS

I. INTRODUCTION..... 1

II. BACKGROUND..... 2

III. POPULATION PK ANALYSIS..... 3

 A. The Two-Stage Approach 4

 B. The Nonlinear Mixed-Effects Modeling Approach 4

IV. WHEN TO USE THE POPULATION PK APPROACH..... 5

V. STUDY DESIGN AND EXECUTION 6

 A. Sampling Designs..... 6

 B. Importance of Sampling Individuals on More Than One Occasion..... 8

 C. Simulation..... 9

 D. Study Protocol 9

 E. Study Execution 11

VI. ASSAY..... 11

VII. DATA HANDLING..... 12

 A. Data Assembly and Editing..... 12

 B. Handling Missing Data 12

 C. Outliers 13

 D. Data Type 13

 E. Data Integrity and Computer Software..... 14

VIII. DATA ANALYSIS..... 14

 A. Exploratory Data Analysis..... 14

 B. Population PK Model Development 15

 C. Model Validation 15

<i>IX. POPULATION PK STUDY REPORT</i>	<i>19</i>
<i>A. Summary</i>	<i>19</i>
<i>B. Introduction</i>	<i>19</i>
<i>C. Objectives, Hypotheses, and Assumptions</i>	<i>19</i>
<i>D. Materials and Methods</i>	<i>19</i>
<i>E. Results</i>	<i>20</i>
<i>F. Discussion</i>	<i>20</i>
<i>G. Application of Results</i>	<i>20</i>
<i>H. Appendix</i>	<i>21</i>
<i>I. Electronic Files</i>	<i>21</i>
<i>X. LABELING</i>	<i>21</i>
<i>XI. USING POPULATION PK STUDIES AND ANALYSIS IN DRUG DEVELOPMENT AND SUBMISSIONS</i>	<i>22</i>
<i>REFERENCES</i>	<i>24</i>
<i>GLOSSARY</i>	<i>29</i>

GUIDANCE FOR INDUSTRY¹

Population Pharmacokinetics

I. INTRODUCTION

This guidance makes recommendations on the use of population pharmacokinetics in the drug development process to help identify differences in drug safety and efficacy among population subgroups. It summarizes scientific and regulatory issues that should be addressed using population pharmacokinetics. The guidance discusses when to perform a population pharmacokinetic study and/or analysis; how to design and execute a population pharmacokinetic study; how to handle and analyze population pharmacokinetic data; what model validation methods are available; and how to provide appropriate documentation for population pharmacokinetic reports intended for submission to the FDA. Although the information in this guidance for industry focuses on population pharmacokinetics, the principles discussed here are equally applicable to population pharmacodynamic and toxicokinetic studies.²

Because the analysis of drug safety and efficacy among population subgroups is a rapidly evolving area of drug development and regulation, frequent communication between the sponsor and the FDA review staff is encouraged throughout the drug development process.

Pharmaceutical industry scientists and the FDA have long been interested in the use of population pharmacokinetics/pharmacodynamics in the analysis of drug safety and efficacy among population subgroups (1). Reference is made to this subject in other FDA guidance documents, including *General Considerations for the Clinical Evaluation of Drugs* (FDA 77-3040) and in International Conference on Harmonisation (ICH) guidances, including *E4 Dose-Response Information to Support Drug Registration*, and *E7 Studies in Support of Special Populations: Geriatrics*.³ These guidance documents support the use of special data collection and analysis methodologies, such as the population pharmacokinetic approach (population PK approach), as part of the

¹ This guidance has been prepared by the Population Pharmacokinetic Working Group of the Clinical Pharmacology Section of the Medical Policy Coordinating Committee in the Center for Drug Evaluation and Research (CDER) in cooperation with the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration. This guidance document represents the Agency's current thinking on population pharmacokinetics in drug evaluation. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute, regulations, or both.

² A separate guidance on pharmacokinetic and pharmacodynamic modeling is in preparation.

³ A guidance for industry on general considerations for pediatric pharmacokinetic studies is in preparation.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.